Nymox Pharmaceutical Corporation (Bahamas) - ADR
$0.47
$-0.06
(-11.77%)
As on 07-Sep-2023 09:30EDT
Market cap
$18 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
48
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-1 Mln
-
ROE
-6.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
91,265,104
10 Years Aggregate
CFO
$-66.99 Mln
EBITDA
$-106.47 Mln
Net Profit
$-108.66 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nymox Pharmaceutical Corporation (Bahamas) - ADR
| 46.1 | -53.2 | 14.0 | 16.9 | -43.3 | -29.0 | -24.4 |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Nymox Pharmaceutical Corporation (Bahamas) - ADR
| -75.4 | -47.6 | 12.7 | 67.9 | -60.1 | 23.6 | -18.6 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Nymox Pharmaceutical Corporation (Bahamas) - ADR
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate... (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas. Read more
-
Founder, Chairman, CEO & Pres
Dr. Paul Averback DABP, M.D.
-
Founder, Chairman, CEO & Pres
Dr. Paul Averback DABP, M.D.
-
Headquarters
Nassau
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Nymox Pharmaceutical Corporation (Bahamas) - ADR
What is the current share price of Nymox Pharmaceutical Corporation (Bahamas) - ADR Today?
The share price of Nymox Pharmaceutical Corporation (Bahamas) - ADR is $0.47 (NASDAQ) as of 07-Sep-2023 09:30 EDT. Nymox Pharmaceutical Corporation (Bahamas) - ADR has given a return of -43.26% in the last 3 years.
What is the current PB & PE ratio of Nymox Pharmaceutical Corporation (Bahamas) - ADR?
Since, TTM earnings of Nymox Pharmaceutical Corporation (Bahamas) - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
What is the 52 Week High and Low of Nymox Pharmaceutical Corporation (Bahamas) - ADR?
The 52-week high and low of Nymox Pharmaceutical Corporation (Bahamas) - ADR are Rs -- and Rs -- as of 08-Sep-2026.
What is the market cap of Nymox Pharmaceutical Corporation (Bahamas) - ADR?
Nymox Pharmaceutical Corporation (Bahamas) - ADR has a market capitalisation of $ 18 Mln as on 07-Sep-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Nymox Pharmaceutical Corporation (Bahamas) - ADR?
Before investing in Nymox Pharmaceutical Corporation (Bahamas) - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.